Morovati Hamid, Eslami Saba, Farzaneh Bonab Hesam, Kord Mohammad, Darabian Sima
Department of Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Central Research Laboratory, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Iran J Microbiol. 2022 Oct;14(5):624-635. doi: 10.18502/ijm.v14i5.10955.
There is a poor understanding about the prevalence and characteristics of secondary bacterial and fungal infections among Coronavirus diseases 2019 (COVID-19) superinfection in hospitalized patients.
Four hundred COVID-19-proven patients were enrolled in this study. Nasal swabs for molecular assay (Real-time PCR) and sputum samples for further microbiological assays were collected. Following a broad-spectrum search, a meta-analysis was performed using StatsDirect software (version 2.7.9) according to the DerSimonian and Laird method applying the random-effects models.
spp. (21.5%) and spp (16.7%) had the highest prevalence of bacterial coinfection among the COVID-19 patients, while spp. had the lowest prevalence (4.2%). Among fungal coinfections, was the most prevalent (6.7%), and spp. was the lowest (2%). Males, elderly patients, patients with a history of underlying diseases and drug use, patients who showed acute clinical symptoms, and patients with a prolonged hospital stay had a higher incidence of secondary infections (P-value <0.05). The pooled prevalence for bacterial and fungal coinfections was 33.52% (95% CI: 18.12 to 50.98; I: 99.4%; P-value: <0.0001).
We suggest designing additional research with a larger target population and diagnostic molecular analyses to depict a more realistic view of the coinfection status.
对于住院的2019冠状病毒病(COVID-19)患者继发细菌和真菌感染的患病率及特征,人们了解不足。
本研究纳入了400例经证实感染COVID-19的患者。采集用于分子检测(实时荧光定量PCR)的鼻拭子和用于进一步微生物检测的痰标本。经过广泛检索后,使用StatsDirect软件(版本2.7.9),根据DerSimonian和Laird方法并应用随机效应模型进行荟萃分析。
在COVID-19患者中,[具体细菌种类1](21.5%)和[具体细菌种类2](16.7%)的细菌合并感染患病率最高,而[具体细菌种类3]的患病率最低(4.2%)。在真菌合并感染中,[具体真菌种类1]最为常见(6.7%),而[具体真菌种类2]最低(2%)。男性、老年患者、有基础疾病和用药史的患者、出现急性临床症状的患者以及住院时间延长的患者继发感染的发生率较高(P值<0.05)。细菌和真菌合并感染的汇总患病率为33.52%(95%置信区间:18.12至50.98;I²:99.4%;P值:<0.0001)。
我们建议设计针对更大目标人群的进一步研究以及诊断性分子分析,以更真实地描绘合并感染状况。